<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887627</url>
  </required_header>
  <id_info>
    <org_study_id>087-CL-094</org_study_id>
    <nct_id>NCT00887627</nct_id>
  </id_info>
  <brief_title>Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild &amp; Moderate Kidney Function Impairment to Subjects With Normal Kidney Function</brief_title>
  <official_title>A Phase 1, Open-Label Study to Assess the Effects of Renal Impairment on the Pharmacokinetics of Intravenous Conivaptan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to compare a conivaptan PK in subjects with mild or moderate kidney function
      impairment to subjects with normal kidney function after a 48-hour continuous infusion of
      conivaptan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure PK and protein binding of conivaptan</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure safety and tolerability of conivaptan</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Kidney Diseases</condition>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>1. Mild Renal Function Impaired Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Moderate Renal Function Impaired Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Subjects with Normal Renal Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conivaptan hydrochloride</intervention_name>
    <description>intravenous</description>
    <arm_group_label>1. Mild Renal Function Impaired Subjects</arm_group_label>
    <arm_group_label>2. Moderate Renal Function Impaired Subjects</arm_group_label>
    <arm_group_label>3. Subjects with Normal Renal Function</arm_group_label>
    <other_name>Vaprisol</other_name>
    <other_name>YM087</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weighs at least 45 kg

          -  Body mass index between 18 and 40 kg/m2 inclusive

          -  Must be in good health other than renal function impairment and related stable
             diseases for the renal impaired subjects

          -  Must have a screening and pre-dose estimated glomerular filtration rate (GFR) that
             corresponds with the level of renal impairment based on the abbreviated Modification
             of Diet in Renal Disease (MDRD) formula

          -  Female subject of child-bearing potential must not be pregnant or lactating, must have
             a negative pregnancy test, utilizes adequate contraceptive methods while in this study
             or may be surgically sterile and/or two years post menopausal

        Exclusion Criteria:

          -  Subject is known to be HIV positive or has HIV antibodies

          -  Has clinically significant history or presence of illness, medical condition, or
             laboratory abnormality

          -  Is Hepatitis positive

          -  Subject with renal impairment has not been on a stable dose of concomitant medications
             for at least 4 weeks prior to start of study and/or dose changes are likely during the
             study

          -  History of substance abuse within 6 months prior to screening

          -  Has clinically significant history or presence of psychiatric illness, malignancy, or
             immunodeficiency syndrome

          -  Has abnormal liver function tests (ALT, AST, and/or bilirubin)

          -  Has had a blood transfusion or donated/lost more than 450ml of blood within 56 days of
             study drug administration or has donated plasma within 7 days prior to study drug
             administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Art Wheeler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cumberland Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=421</url>
    <description>Link to results on JAPIC</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2009</study_first_posted>
  <last_update_submitted>April 30, 2014</last_update_submitted>
  <last_update_submitted_qc>April 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Protein Binding</keyword>
  <keyword>Conivaptan</keyword>
  <keyword>Vaprisol</keyword>
  <keyword>Kidney Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conivaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

